By Fineline Cube 
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi’s cutting-edge AI-driven drug discovery platform.
AI-Driven Drug Discovery Platform
XtalPi’s platform integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies will co-identify targets and discover first-in-class or best-in-class drug candidates. This innovative approach combines AI’s speed and generative power with the accuracy of robotic experimentation, significantly expanding the chemical space for drug discovery.
Dong-A ST’s Strategic Expansion
Dong-A ST aims to strengthen its pipeline in immunology and inflammation and expand its R&D scope beyond small molecule therapeutics. The company will actively participate in the entire R&D process, leveraging its expertise in immunology, inflammation, and small molecule drug development.
Future Collaboration and Commercial Potential
The partnership highlights Dong-A ST’s commitment to diversifying its R&D portfolio and exploring new commercialization opportunities. By combining XtalPi’s advanced technology with Dong-A ST’s rich experience, the collaboration is poised to drive innovation and address unmet medical needs in immunological and inflammatory diseases.-Fineline Info & Tech